Towards the development of 5-HT7 ligands combining serotonin-like and arylpiperazine moieties

Add time:07/14/2019    Source:sciencedirect.com

Many known 5-HT7 ligands contain either a serotonin-like or an arylpiperazine structure that, in published SAR studies, are generally supposed to bind the same receptor pocket. Conversely, we explored the hypothesis that two such moieties can co-exist in the same ligand, binding to different pockets. We thus designed and synthesized a set of compounds including both a 5-hydroxyindol-3-ylethyl and a 1-arylpiperazine moieties connected by a short linker. The compounds were tested for their affinity for human 5-HT7 serotonin receptor. We further prepared a novel series of 5-HT7 ligands, where the 5-hydroxyindol-3-ylethyl moiety was bioisosterically replaced by a 3-hydroxyanilinoalkyl one. Among the newly synthesized compounds, potent ligands at the 5-HT7 receptor, behaving as antagonists in functional tests, were identified, even if they showed limited subtype selectivity. Docking studies within a model of the 5-HT7 receptor showed that the binding site can actually accommodate both moieties, with the serotonin-like one in the putative orthosteric site and the arylpiperazine one occupying an accessory pocket. The present results demonstrate that it is possible to devise and develop new 5-HT7 ligands merging two privileged structures in the same molecule.

We also recommend Trading Suppliers and Manufacturers of 5-[(5-chloro-2-hydroxyanilino)methylene]-1-(3-chlorophenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione (cas 332027-88-0). Pls Click Website Link as below: cas 332027-88-0 suppliers

Prev:A solvatochromic study of N-[4-(9-acridinylamino)-3-methoxyphenyl]methanesulfonamide hydrochloride: An experimental and theoretical approach
Next:DFT Studies on Nonlinear Optical Properties of N-[(Naphthalen-5-yl)methyl]-4-Nitrobenzamine)